A delegation of 15 EIC-backed companies will present their biotech solutions at BIO International Convention 2025, taking place from 16 to 19 June in Boston, US. The companies will take part in the European Innovation Council (EIC) Pavilion, which will bring European innovation into the spotlight at BIO 2025 with the backing of the EIC International Trade Fairs Programme 3.0. An initiative of the EIC Business Acceleration Services, this programme will provide EIC-backed innovators with a valuable platform to connect with biotech industry leaders and build international partnerships globally.
As the largest and most influential event in biotechnology, the BIO International Convention 2025 is expected to attract over 20,000 professionals from across the biotech and life sciences industries worldwide. The convention features more than 120 sessions on a wide range of topics, including AI advancements, digital health, biomanufacturing, gene therapy, oncology, and patient advocacy.
This event offers exclusive networking opportunities for companies to connect with global biotech leaders, government officials, investors, and researchers from both the US and around the world. Last year, BIO welcomed more than 19,500 attendees and 1,500 exhibitors and held over 61,500 partnering meetings with participation from 70 countries and 150 US and international public officials.
Take a look at the highlights from the last edition at the EIC Pavilion in this recap video.
Meet the EIC-backed innovators
The 15 EIC-backed companies selected to showcase their innovations at BIO 2025 are:
- Ability Pharmaceuticals (Spain): First-class oral anticancer compounds inducing autophagy-mediated cytotoxicity.
- Acorai (Sweden): Non-invasive handheld device for measuring cardiac and pulmonary pressures.
- Acousort (Sweden): Microfluidic based products automating biological sample preparation.
- Aortyx (Spain): Promotes regeneration by mimicking natural biomechanical properties.
- Arctic Therapeutics (Iceland): Transforming drug development by using the power of applied genomics.
- BestHealth4U (Portugal): Bio2Skin offers strong and reliable adhesion while being gentle on the skin.
- Ezmems (Israel): A polymeric multisensor chip, delivering precise and real-time data.
- Genera Research (Croatia): OSTEOGROW-C bone regeneration implant transforms blood into bone.
- Hemispherian (Norway): GLIX1 is an entirely new way of treating brain cancers.
- Qubit Pharmaceuticals (France): Pioneering quantum-aided simulation and design to discover novel therapeutics.
- SiriusXT (Ireland): First lab-based soft X-ray microscope for intact whole-cell imaging.
- Spartha Medical (France): Providing antimicrobial, proregenerative, antiviral and antifungal solutions.
- Tafalgie Therapeutics (France): Non-opioid pain-relieving peptides without side effects of traditional treatments.
- Glycanostics (Slovakia): Highly accurate, early-stage cancer diagnostic tests for tumour detection.
- Spika Tech (Spain): Real-time 3D heart rhythm visualisation for diagnostics and treatment.
On 6 May, an online pre-departure workshop was held with the 15 EIC-funded companies, EIC representatives, and market experts. The goal of the workshop was to prepare the selected companies for BIO 2025 by providing detailed information about the trade fair opportunities and explaining the approach to onsite matchmaking services.
Leading up to the event, these EIC companies will receive additional coaching services and participate in various matchmaking activities, including reverse pitch sessions and one-on-one meetings with potential investors and business partners.
Stay up to date
The EIC International Trade Fairs Programme 3.0 is an initiative of the EIC Business Acceleration Services.
Be the first to receive the latest updates on open calls for applications, inspiring success stories, exclusive interviews, partner opportunities, and other engaging news from the EIC Business Acceleration Services with the EIC BAS Newsletter.
DISCLAIMER: This information is provided in the interest of knowledge sharing and should not be interpreted as the official view of the European Commission, or any other organisation.